학술논문

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers
Document Type
Abstract
Source
In Blood 16 November 2008 112(11):329-329
Subject
Language
ISSN
0006-4971